杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/06/16 | 1,493 | 1,496 | 1,482 | 1,484 | +1 | +0.1% | 62,800 |
| 2025/06/13 | 1,498 | 1,498 | 1,476 | 1,483 | -19 | -1.3% | 137,900 |
| 2025/06/12 | 1,488 | 1,502 | 1,485 | 1,502 | +4 | +0.3% | 92,500 |
| 2025/06/11 | 1,493 | 1,512 | 1,493 | 1,498 | +13 | +0.9% | 98,200 |
| 2025/06/10 | 1,485 | 1,497 | 1,485 | 1,485 | -5 | -0.3% | 64,700 |
| 2025/06/09 | 1,502 | 1,503 | 1,482 | 1,490 | ±0 | ±0% | 56,500 |
| 2025/06/06 | 1,492 | 1,498 | 1,481 | 1,490 | -1 | -0.1% | 43,500 |
| 2025/06/05 | 1,490 | 1,496 | 1,483 | 1,491 | +1 | +0.1% | 57,000 |
| 2025/06/04 | 1,490 | 1,501 | 1,484 | 1,490 | ±0 | ±0% | 62,800 |
| 2025/06/03 | 1,498 | 1,498 | 1,480 | 1,490 | -8 | -0.5% | 70,500 |
| 2025/06/02 | 1,486 | 1,509 | 1,479 | 1,498 | -7 | -0.5% | 121,400 |
| 2025/05/30 | 1,466 | 1,505 | 1,459 | 1,505 | +35 | +2.4% | 318,100 |
| 2025/05/29 | 1,452 | 1,472 | 1,452 | 1,470 | +7 | +0.5% | 133,500 |
| 2025/05/28 | 1,450 | 1,465 | 1,446 | 1,463 | +8 | +0.5% | 122,400 |
| 2025/05/27 | 1,453 | 1,461 | 1,448 | 1,455 | -4 | -0.3% | 83,100 |
| 2025/05/26 | 1,458 | 1,464 | 1,447 | 1,459 | -1 | -0.1% | 81,200 |
| 2025/05/23 | 1,463 | 1,469 | 1,450 | 1,460 | -2 | -0.1% | 99,500 |
| 2025/05/22 | 1,456 | 1,468 | 1,446 | 1,462 | -7 | -0.5% | 89,300 |
| 2025/05/21 | 1,453 | 1,471 | 1,451 | 1,469 | +16 | +1.1% | 77,800 |
| 2025/05/20 | 1,477 | 1,481 | 1,453 | 1,453 | -13 | -0.9% | 130,600 |
| 2025/05/19 | 1,441 | 1,467 | 1,440 | 1,466 | +13 | +0.9% | 129,400 |
| 2025/05/16 | 1,445 | 1,455 | 1,433 | 1,453 | +12 | +0.8% | 79,900 |
| 2025/05/15 | 1,441 | 1,447 | 1,427 | 1,441 | -19 | -1.3% | 98,500 |
| 2025/05/14 | 1,460 | 1,471 | 1,437 | 1,460 | -16 | -1.1% | 120,300 |
| 2025/05/13 | 1,518 | 1,525 | 1,472 | 1,476 | +18 | +1.2% | 145,900 |
| 2025/05/12 | 1,488 | 1,495 | 1,458 | 1,458 | -30 | -2% | 125,000 |
| 2025/05/09 | 1,466 | 1,495 | 1,460 | 1,488 | +24 | +1.6% | 66,700 |
| 2025/05/08 | 1,478 | 1,481 | 1,454 | 1,464 | -6 | -0.4% | 73,400 |
| 2025/05/07 | 1,473 | 1,479 | 1,455 | 1,470 | -16 | -1.1% | 73,400 |
| 2025/05/02 | 1,471 | 1,492 | 1,471 | 1,486 | +11 | +0.7% | 78,800 |
| 2025/05/01 | 1,470 | 1,481 | 1,463 | 1,475 | +1 | +0.1% | 88,600 |
| 2025/04/30 | 1,482 | 1,485 | 1,472 | 1,474 | -8 | -0.5% | 104,400 |
| 2025/04/28 | 1,491 | 1,499 | 1,482 | 1,482 | +5 | +0.3% | 110,200 |
| 2025/04/25 | 1,503 | 1,505 | 1,477 | 1,477 | -18 | -1.2% | 140,700 |
| 2025/04/24 | 1,508 | 1,517 | 1,487 | 1,495 | -23 | -1.5% | 171,100 |
| 2025/04/23 | 1,488 | 1,553 | 1,481 | 1,518 | +42 | +2.8% | 653,200 |
| 2025/04/22 | 1,476 | 1,487 | 1,464 | 1,476 | ±0 | ±0% | 52,100 |
| 2025/04/21 | 1,464 | 1,476 | 1,462 | 1,476 | ±0 | ±0% | 40,300 |
| 2025/04/18 | 1,465 | 1,479 | 1,453 | 1,476 | +28 | +1.9% | 48,500 |
| 2025/04/17 | 1,446 | 1,454 | 1,431 | 1,448 | +7 | +0.5% | 69,500 |
| 2025/04/16 | 1,447 | 1,449 | 1,434 | 1,441 | -4 | -0.3% | 69,600 |
| 2025/04/15 | 1,428 | 1,445 | 1,428 | 1,445 | +19 | +1.3% | 57,300 |
| 2025/04/14 | 1,424 | 1,432 | 1,423 | 1,426 | +9 | +0.6% | 62,600 |
| 2025/04/11 | 1,381 | 1,417 | 1,370 | 1,417 | -11 | -0.8% | 133,400 |
| 2025/04/10 | 1,440 | 1,440 | 1,407 | 1,428 | +63 | +4.6% | 110,200 |
| 2025/04/09 | 1,372 | 1,381 | 1,356 | 1,365 | -37 | -2.6% | 171,800 |
| 2025/04/08 | 1,400 | 1,402 | 1,375 | 1,402 | +37 | +2.7% | 143,300 |
| 2025/04/07 | 1,350 | 1,393 | 1,332 | 1,365 | -66 | -4.6% | 235,800 |
| 2025/04/04 | 1,437 | 1,463 | 1,417 | 1,431 | -26 | -1.8% | 261,500 |
| 2025/04/03 | 1,441 | 1,458 | 1,432 | 1,457 | -10 | -0.7% | 142,000 |
1～
50
件表示中 / 3721件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 148,400円 | -2.4% | -52.3% | 3.84% | 17.76倍 | 0.63倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 202,100円 | +3.1% | -6.5% | 2.38% | 9.38倍 | 0.99倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ハートシード | 431,500円 | +174.2% | - | 0.00% | - | 12.95倍 |
|
慶応大学発ベンチャー。ｉＰＳ細胞を使い独自の心筋再生用心筋球で重症心不全治療を目指す |
| 栄研化 | 220,000円 | +4.1% | -3.1% | 2.64% | 19.16倍 | 1.67倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ネクセラファーマ | 92,000円 | +20.3% | - | 0.00% | 163.12倍 | 1.22倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム
